Actinium Pharmaceuticals (ATNM) Receives a Buy from Maxim Group


Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM) today and set a price target of $3. The company’s shares opened today at $0.70.

McCarthy said:

“Actinium reported positive preclinical data from its Iomab-ACT (CD45- targeting) next-generation lymphodepletion program for CAR-T at the 2019 Transplantation & Cellular Therapy (TCT) meetings of ASBMT and CIBMTR being held in Houston, TX (data is discussed below).”

According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.3% and a 33.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Aridis Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.

Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $4.67.

See today’s analyst top recommended stocks >>

Based on Actinium Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $6.15 million. In comparison, last year the company had a GAAP net loss of $5.16 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts